Cover Image
市場調查報告書

經腔性末稍血管形成的藥物釋放型球囊 (DEB)的全球市場:醫療設備的開發平台評估

Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 365828
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
經腔性末稍血管形成的藥物釋放型球囊 (DEB)的全球市場:醫療設備的開發平台評估 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年08月01日 內容資訊: 英文 87 Pages
簡介

本報告提供全球經腔性末稍血管形成 (PTA) 的藥物釋放型球囊 (DEB) 市場上,主要開發中產品與其臨床實驗的進展調查,產品的功能、特性比較分析 (臨床實驗的進展各階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (業績報告、資本交易趨勢等) 的資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 經腔性末稍血管形成 (PTA) 的藥物釋放型球囊 (DEB)的概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 開發中產品:現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • PTA的DEB的企業:各臨床實驗階段的開發中產品
  • PTA的DEB:各臨床實驗階段的開發中產品

第5章 PTA的DEB市場:企業、產品概要

  • AnGes MG, Inc.
    • 開發中產品及進行中的臨床實驗概要
  • AngioCure, Inc.
  • AVIDAL Vascular GmbH
  • Bayer HealthCare AG
  • Contego Medical, LLC
  • Elixir Medical Corporation
  • eucatech AG
  • Lifetech Scientific (Shenzhen) Co., Ltd.
  • Medtronic plc Company
  • Micell Technologies, Inc.
  • Nipro
  • NuVascular Technologies Inc
  • QT Vascular Ltd.
  • QualiMed Innovative Medizinprodukte GmbH
  • Rontis AG
  • SiL Vascular Ltd
  • SurModics, Inc.
  • Terumo Corporation
  • The Spectranetics Corporation
  • Vascular Nanotransfer Technologies

第6章 PTA的DEB市場:目前的趨勢 (共35件)

第7章 附錄

圖表一覽

目錄
Product Code: GDME0216EPD

GlobalData's Medical Devices sector report, "Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016" provides an overview of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Overview

3. Products under Development

  • 3.1. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
  • 3.2. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
  • 3.3. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
  • 3.4. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
  • 3.5. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials

4. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies

  • 4.1. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
  • 4.2. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development

5. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview

  • 5.1. AnGes MG, Inc. Company Overview
    • 5.1.1. AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. AngioCure, Inc. Company Overview
    • 5.2.1. AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. AVIDAL Vascular GmbH Company Overview
    • 5.3.1. AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Bayer HealthCare AG Company Overview
    • 5.4.1. Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Contego Medical, LLC Company Overview
    • 5.5.1. Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Elixir Medical Corporation Company Overview
    • 5.6.1. Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. eucatech AG Company Overview
    • 5.7.1. eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview
    • 5.8.1. Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Medtronic plc Company Overview
    • 5.9.1. Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Micell Technologies, Inc. Company Overview
    • 5.10.1. Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Nipro Corporation Company Overview
    • 5.11.1. Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. NuVascular Technologies Inc Company Overview
    • 5.12.1. NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. QT Vascular Ltd. Company Overview
    • 5.13.1. QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. QualiMed Innovative Medizinprodukte GmbH Company Overview
    • 5.14.1. QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Rontis AG Company Overview
    • 5.15.1. Rontis AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. SiL Vascular Ltd Company Overview
    • 5.16.1. SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. SurModics, Inc. Company Overview
    • 5.17.1. SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Terumo Corporation Company Overview
    • 5.18.1. Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. The Spectranetics Corporation Company Overview
    • 5.19.1. The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Vascular Nanotransfer Technologies Company Overview
    • 5.20.1. Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview

6. Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Recent Developments

  • 6.1. Jul 21, 2016: Federal Circuit Court Rules in Appeal
  • 6.2. Jul 20, 2016: 12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium
  • 6.3. Jul 15, 2016: Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036
  • 6.4. Jul 15, 2016: Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046
  • 6.5. Jul 13, 2016: Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths
  • 6.6. Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
  • 6.7. Jun 30, 2016: FTSE Russell Selects Daiichi Sankyo for FTSE4Good Global Index
  • 6.8. Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic
  • 6.9. Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
  • 6.10. Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day
  • 6.11. Jun 01, 2016: Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics' Stellarex drug-coated balloon at NCVH
  • 6.12. May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
  • 6.13. May 16, 2016: iVascular Receives CE Mark Approval for LUMINOR 18 Drug Eluting Balloon
  • 6.14. May 12, 2016: Daiichi Sankyo Announces Changes to Representative Director and Members of the Board
  • 6.15. May 06, 2016: The outcome of arbitration proceeding with certain former shareholders of Ranbaxy
  • 6.16. Apr 26, 2016: 12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics' Stellarex drug-coated balloon at Charing Cross
  • 6.17. Apr 26, 2016: Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases
  • 6.18. Apr 25, 2016: QT Vascular Submits IDE Requesting Permission to Begin Pivotal Trial of Its Drug-Coated Chocolate Balloon in The United States
  • 6.19. Apr 06, 2016: SurModics Announces First Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon
  • 6.20. Feb 10, 2016: QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore
  • 6.21. Jan 26, 2016: BIOTRONIK Announces Expansion Of Passeo-18 Lux Drug-Coated Balloon Portfolio
  • 6.22. Jan 11, 2016: Medtronic IN.PACT Admiral DEB Receives CE Mark For Treatment Of AV Access In Patients With End-Stage Renal Disease
  • 6.23. Dec 14, 2015: Medtronic Announces New High-Tech Facility in Galway; Building on Global Synergies
  • 6.24. Nov 26, 2015: Update On AngioScore Litigation - QT Vascular Ltd
  • 6.25. Nov 20, 2015: BIOTRONIK Announces Improved Patient Outcomes with Innovative "Combination Therapy" for Peripheral Artery Disease
  • 6.26. Nov 02, 2015: IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015
  • 6.27. Nov 02, 2015: Medtronic Begins REALITY Study To Assess IN.PACT Admiral DCB In Patients With PAD
  • 6.28. Oct 14, 2015: Medtronic Drug-Coated Balloon Sustains Superiority Over Balloon Angioplasty at Two Years in Patients with Peripheral Arterial Disease
  • 6.29. Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon
  • 6.30. Oct 05, 2015: QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch
  • 6.31. Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon
  • 6.32. Sep 15, 2015: New Technique at Morris Hospital Improves Treatment of Peripheral Artery Disease
  • 6.33. Sep 07, 2015: QT Vascular Announces CE Mark Clearance Of Chocolate Touch By LRQA 0088
  • 6.34. Aug 03, 2015: CMS Grants New Technology Add-On Payment for Inpatient Use of Medtronic's Drug-Coated Balloon
  • 6.35. Jul 29, 2015: Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex Drug-Coated Balloon Technology

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
  • Table 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
  • Table 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
  • Table 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
  • Table 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
  • Table 6: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
  • Table 7: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
  • Table 8: AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Collategene Drug-Eluting Balloon Catheter - Product Status
  • Table 10: Collategene Drug-Eluting Balloon Catheter - Product Description
  • Table 11: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status
  • Table 12: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description
  • Table 13: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 14: AngioCure TOP-C Smart Balloon Catheter - Product Status
  • Table 15: AngioCure TOP-C Smart Balloon Catheter - Product Description
  • Table 16: AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 17: WOMBAT - Peripheral Version - Product Status
  • Table 18: WOMBAT - Peripheral Version - Product Description
  • Table 19: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 20: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Status
  • Table 21: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Description
  • Table 22: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 23: Tibial Artery Drug Eluting Balloon - Product Status
  • Table 24: Tibial Artery Drug Eluting Balloon - Product Description
  • Table 25: Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: Peripheral Vascular Resorbable Scaffold - Product Status
  • Table 27: Peripheral Vascular Resorbable Scaffold - Product Description
  • Table 28: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 29: Support - Product Status
  • Table 30: Support - Product Description
  • Table 31: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: PTA Drug Eluting Balloon - Product Status
  • Table 33: PTA Drug Eluting Balloon - Product Description
  • Table 34: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: DCB BTK - Product Status
  • Table 36: DCB BTK - Product Description
  • Table 37: Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: Drug-Coated Balloon - Product Status
  • Table 39: Drug-Coated Balloon - Product Description
  • Table 40: Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Peripheral Drug-Eluting Balloon - Product Status
  • Table 42: Peripheral Drug-Eluting Balloon - Product Description
  • Table 43: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 44: NuSpun DE Balloon - Product Status
  • Table 45: NuSpun DE Balloon - Product Description
  • Table 46: QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 47: Chocolate Touch PTA Drug Coated Balloon - Product Status
  • Table 48: Chocolate Touch PTA Drug Coated Balloon - Product Description
  • Table 49: Silk PTA Balloon Catheter - Product Status
  • Table 50: Silk PTA Balloon Catheter - Product Description
  • Table 51: QT Vascular Ltd. - Ongoing Clinical Trials Overview
  • Table 52: Chocolate Touch PTA Drug Coated Balloon - First in Human Evaluation of the Drug-coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease
  • Table 53: Chocolate Touch PTA Drug Coated Balloon - Pivotal Trial of Drug-coated Chocolate Balloon in The United States
  • Table 54: QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 55: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status
  • Table 56: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description
  • Table 57: Rontis AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 58: Drug Eluting Dilatation Catheter - Product Status
  • Table 59: Drug Eluting Dilatation Catheter - Product Description
  • Table 60: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 61: Peripheral Vascular Balloon - Product Status
  • Table 62: Peripheral Vascular Balloon - Product Description
  • Table 63: SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 64: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status
  • Table 65: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description
  • Table 66: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status
  • Table 67: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description
  • Table 68: SurVeil Drug Coated Balloon - SFA - Product Status
  • Table 69: SurVeil Drug Coated Balloon - SFA - Product Description
  • Table 70: SurModics, Inc. - Ongoing Clinical Trials Overview
  • Table 71: SurVeil Drug Coated Balloon - SFA - A Prospective, Multi-center, Single-arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery
  • Table 72: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 73: Drug Coated Balloon Catheter - Product Status
  • Table 74: Drug Coated Balloon Catheter - Product Description
  • Table 75: The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 76: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Status
  • Table 77: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Description
  • Table 78: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Status
  • Table 79: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Description
  • Table 80: The Spectranetics Corporation - Ongoing Clinical Trials Overview
  • Table 81: Stellarex Drug Coated Balloon - Superficial Femoral Artery - ILLUMENATE First-in-Human (FIH) Study on the Safety and Effectiveness of Covidien's Advanced Drug-coated Balloon (DCB) Technology
  • Table 82: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Global Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery and/or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon (ILLUMENATE GLOBAL)
  • Table 83: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Multi-center, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon
  • Table 84: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Stellarex Vascular E-Registry
  • Table 85: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • Table 86: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status
  • Table 87: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description
  • Table 88: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status
  • Table 89: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description
  • Table 90: Glossary

List of Figures

  • Figure 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
  • Figure 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
  • Figure 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
  • Figure 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
  • Figure 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
Back to Top